novo nordisk amycretin - Search News

News

Obesity, Novo Nordisk and Amycretin

Insider Monkey on MSN · 1d

Novo Nordisk Fast-Tracks Amycretin to Phase 3 for Obesity Treatment

Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development.

The Wall Street Journal on MSN · 3d

Novo Nordisk’s New Obesity Drug Beats Wegovy Weight Loss in Early Trial

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Clinical Trials Arena on MSN · 13d

Novo Nordisk ramps up obesity fight, advances amycretin to Phase III

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting, Novo Nordisk shared that regulatory authorities have approved the therapy to proceed.

Fierce Biotech3d

Novo's injectable amycretin yet to hit weight loss plateau, suggesting Zepbound-beating potential

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

The Manila Times6d

Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an ...

1don MSN

Novo Nordisk A/S (NVO): A Bull Case Theory

We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will ...

Novo Leans on CagriSema’s Safety as Amycretin Moves Forward to Phase III

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

3don MSN

Experimental drug helps patients lose nearly a quarter of body weight in early trials

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

3d

Novo Nordisk falls as CagriSema obesity data shows no clear edge vs Zepbound

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

ADA: Novo continues effort to rehabilitate CagriSema

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results